NCT03871244

Brief Summary

The Pilot Optimizing Transfusion Thresholds in Critically-ill Children with Anaemia (P-OpTTICCA) study is a pilot trial for a large pragmatic international parallel open-label non-inferiority randomised controlled trial. The primary outcome of the pilot study is feasibility.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
120

participants targeted

Target at P25-P50 for phase_3

Timeline
Completed

Started Jun 2020

Typical duration for phase_3

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 6, 2019

Completed
6 days until next milestone

First Posted

Study publicly available on registry

March 12, 2019

Completed
1.2 years until next milestone

Study Start

First participant enrolled

June 3, 2020

Completed
1.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2021

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2022

Completed
Last Updated

September 28, 2021

Status Verified

September 1, 2021

Enrollment Period

1.6 years

First QC Date

March 6, 2019

Last Update Submit

September 22, 2021

Conditions

Keywords

hemoglobin thresholdcritically ill childrenrandomized controlled trialred blood cell tranfusions

Outcome Measures

Primary Outcomes (3)

  • Recruitment: screening

    Proportion of patients eligible for consent approached \> 90%;

    One year

  • Recruitment: consent

    Proportion of approached patients who decline consent \< 20%,

    One year

  • Recruitment: enrolment

    Recruitment: ≥ 2 patients randomized/site/week.

    One year

Secondary Outcomes (8)

  • Representativeness: exclusion

    One year

  • Representativeness: opt-out

    One year

  • Compliance

    One year

  • Separation

    One year

  • Suspension

    One year

  • +3 more secondary outcomes

Study Arms (2)

Restrictive arm (intervention)

EXPERIMENTAL

Less red blood cell transfusions. The protocol will require that no red blood cell transfusion be given unless the hemoglobin level is below or equal at 70 g per L.

Procedure: Less red blood cell transfusions

Standard care arm (comparator)

ACTIVE COMPARATOR

Clinical teams will follow their usual transfusion practices.

Procedure: More red blood cell transfusion (standard transfusion strategy in PICU)

Interventions

The instructions given to caregivers will be to consider prescribing a red blood cell transfusion only if the hemoglobin level is ≤ 70 g per L.

Also known as: Restrictive red blood cell transfusion strategy
Restrictive arm (intervention)

The instructions given to caregivers will be to prescribe a red blood cell transfusion according to their usual standard practice

Standard care arm (comparator)

Eligibility Criteria

Age1 Day - 18 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • \. Hemoglobin concentration ≤ 95 g/L, while in PICU
  • \. Not already participating to a randomized controlled trial on hemoglobin threshold to guide red blood cell transfusion practice

You may not qualify if:

  • Post conception age ≤ 36 weeks or \> 18 years at PICU entry
  • Refusal of consent by patient and/or parent
  • Uncorrected cyanotic cardiac disease, univentricular physiology
  • Sickle cell disease
  • Brain Death
  • Extracorporeal membrane oxygenation (ECMO)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

CHU Sainte-Justine

Montreal, Quebec, H3T 1C5, Canada

RECRUITING

Related Publications (4)

  • Carson JL, Stanworth SJ, Dennis JA, Fergusson DA, Pagano MB, Roubinian NH, Turgeon AF, Valentine S, Trivella M, Doree C, Hebert PC. Transfusion thresholds and other strategies for guiding red blood cell transfusion. Cochrane Database Syst Rev. 2025 Oct 20;10(10):CD002042. doi: 10.1002/14651858.CD002042.pub6.

  • Tucci M, Sarfatti A, Leteurtre S, Du Pont-Thibodeau G, Fontela P, Ray S, Stanworth SJ, Hebert PC, Roumeliotis N, Sauthier M, Spinella PC, Ducruet T, Jouvet P, Masse B, Robitaille N, Trottier H, Lacroix J; Canadian Critical Care Trials Group and the Groupe Francophone de Reanimation et d'Urgences Pediatriques. Pilot-Optimizing Transfusion Therapy in Critically Ill Children With Anemia: A Pilot Multicenter Electronic Health Record-Enabled Randomized Controlled Trial on Red Blood Cell Transfusion in Critically Ill Children. Pediatr Crit Care Med. 2025 Oct 1;26(10):e1218-e1230. doi: 10.1097/PCC.0000000000003822. Epub 2025 Sep 12.

  • Radford M, Estcourt LJ, Sirotich E, Pitre T, Britto J, Watson M, Brunskill SJ, Fergusson DA, Doree C, Arnold DM. Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem cell support. Cochrane Database Syst Rev. 2024 May 23;5(5):CD011305. doi: 10.1002/14651858.CD011305.pub3.

  • Carson JL, Stanworth SJ, Dennis JA, Trivella M, Roubinian N, Fergusson DA, Triulzi D, Doree C, Hebert PC. Transfusion thresholds for guiding red blood cell transfusion. Cochrane Database Syst Rev. 2021 Dec 21;12(12):CD002042. doi: 10.1002/14651858.CD002042.pub5.

MeSH Terms

Conditions

Anemia

Condition Hierarchy (Ancestors)

Hematologic DiseasesHemic and Lymphatic Diseases

Study Officials

  • Jacques Lacroix

    St-Justine Hospital Center

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: parallel open-label pragmatic non-inferiority randomised controlled trial (RCT)
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

March 6, 2019

First Posted

March 12, 2019

Study Start

June 3, 2020

Primary Completion

December 31, 2021

Study Completion

December 31, 2022

Last Updated

September 28, 2021

Record last verified: 2021-09

Data Sharing

IPD Sharing
Will not share

The data of P-OpTTICCA will be integrated in the large trial if possible. This will not be possible if P-OpTTICCA shows that significant changes must be made to the research proposal of the full trial; then the data of participants of P-OpTTICCA will be merged to the data of the full trial using a meta-analysis strategy.

Locations